Quince Therapeutics Inc
NASDAQ:QNCX

Watchlist Manager
Quince Therapeutics Inc Logo
Quince Therapeutics Inc
NASDAQ:QNCX
Watchlist
Price: 1.6 USD -0.62% Market Closed
Market Cap: 85.9m USD

EV/EBIT
Enterprise Value to EBIT

-1.6
Current
0.4
Median
6.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1.6
=
Enterprise Value
68.1m USD
/
EBIT
-42.7m USD
EBIT Growth EV/EBIT to Growth
US
Quince Therapeutics Inc
NASDAQ:QNCX
Average EV/EBIT: 18.4
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 000.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.4
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.7
17%
1.2
AU
CSL Ltd
ASX:CSL
17.5
14%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
12%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -319.5 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.4
2-Years Forward
EV/EBIT
-1.3
3-Years Forward
EV/EBIT
-1.3